Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Renewed Strategic Approach Needed, Says The British Heart Foundation
In response to the inquiry report into "Was the NHS Plan really a blueprint for the NHS - 10 years on?" released by the All Party Parliamentary Group Primary Care & Public Health today. Mubeen Bhutta Policy Manager at the British Heart Foundation said:
generic viagra online
Double Success For Instituto Gulbenkian De Ciencia Scientists Working On Chromosome Segregation
Lars Jansen"s work on the formation of the centromere, a key cellular structure in powering and controlling chromosome segregation and accurate cell division, has just earned him a paper in Nature Cell Biology and a prestigious EMBO installation grant, of 50,000 euro per year, for a maximum of five years.
News of the day
The Risk Factors For Sporadic Colorectal Cancer
Colorectal cancer (CRC) is one of the most common cancers in China. Although the association between the epidemiological factors and sporadic colorectal cancer has been studied, the relation between smoking, alcohol drinking, family history of cancer, body mass index (BMI) and sporadic colorectal cancer still remains uncertain. So it is important to investigate the role of these factors in the development of sporadic colorectal cancer.
Diagnostics

CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season

CSL Biotherapies, a subsidiary of one of the world"s leading manufacturers of thimerosal-free seasonal influenza vaccine, announced that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes. CSL Biotherapies" seasonal flu vaccine is indicated for the active immunization of persons age 18 years and older against influenza disease (commonly referred to as the "flu") caused by influenza virus subtypes A and type B present in the vaccine. "CSL Biotherapies" early delivery of seasonal influenza vaccine to the U.S. clearly demonstrates our ability to rapidly optimize vaccine production in order to meet evolving public health needs," said Paul Perreault, President of CSL Biotherapies. "Working with the U.S. government, we are also moving quickly to develop a vaccine to address the H1N1 pandemic. Together, these efforts illustrate the expertise in influenza vaccine development and manufacturing that CSL has so successfully accumulated over the past 40 years." CSL Limited, the parent company of CSL Biotherapies, is the first vaccine manufacturer to initiate human clinical trials of the H1N1 influenza vaccine. First administration in healthy volunteers of CSL"s experimental H1N1 pandemic vaccine began on July 22 , 2009 in Australia. U.S. clinical studies are expected to commence in mid-August. CSL Biotherapies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009